Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.37 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484552 | 0.96 | SMN1; SMN2 (0.43) | CCR3SMN1; SMN2ACKR3MCHR1 | |
| SCHEMBL484714 | 0.95 | CCR3 (0.44) | CCR3SMN1; SMN2ACKR3MCHR1TAOK1 | |
| SCHEMBL485317 | 0.93 | ACKR3 (0.39) | CCR3ACKR3MCHR1TAS1R3TAS1R1 | |
| SCHEMBL485515 | 0.90 | CCR3 (0.44) | CCR3SMN1; SMN2ACKR3MCHR1CDK9 | |
| SCHEMBL484545 | 0.90 | CCR3 (0.42) | CCR3SMN1; SMN2ACKR3MCHR1TAOK1 | |
| SCHEMBL484557 | 0.89 | CYP2D6 (0.41) | SMN1; SMN2ACKR3MCHR1TAS1R3TAS1R1 | |
| SCHEMBL2816320 | 0.89 | MCHR1 (0.45) | CCR3SMN1; SMN2ACKR3MCHR1TAOK1 | |
| SCHEMBL484671 | 0.88 | CCR3 (0.42) | CCR3SMN1; SMN2MCHR1 | |
| SCHEMBL484785 | 0.88 | ACKR3 (0.40) | CCR3ACKR3MCHR1TAS1R3TAS1R1 | |
| SCHEMBL484926 | 0.88 | CCR3 (0.43) | CCR3SMN1; SMN2ACKR3MCHR1TAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | claimed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | claimed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | claimed |
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CCR3 794/4885SMN1; SMN2 3545/4885ACKR3 90/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CCR3 794/4885SMN1; SMN2 3545/4885ACKR3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.